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Background. Intravenous alemtuzumab and ﬂudarabine are eﬀective in combination for the treatment of chronic lymphocytic
leukemia (CLL), but require hospital visits for intravenous injection. We performed a pilot study to assess the safety and eﬃcacy of
outpatient-based oral ﬂudarabine with subcutaneous alemtuzumab (OFSA) for the treatment of relapsed/refractory CLL. Results.
Depending on their response, patients were given two to six 28-day cycles of subcutaneous alemtuzumab 30mg on days 1, 3, and
5 and oral ﬂudarabine 40mg/m2/day for 5 days. Median patient age was 74. The lymphocyte counts of all ﬁve patients fell after the
1stcycleoftreatmentandreachednormal/lowlevelsoncompletionof2to6cyclesoftherapy.Plateletcountsandhemoglobinwere
unaﬀected. All ﬁve patients achieved complete hematological remission, while two attained minimal residual disease negativity on
4-color ﬂow cytometry. Conclusions. Our OFSA regimen was eﬀective in elderly Asian patients with relapsed/refractory CLL, and
it should be investigated further.
Copyright © 2009 William Y. K. Hwang et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Background
Chronic lymphoproliferative disorders are considered rare
in Asian countries. A recent 3-year study of 342 con-
secutive leukemia patients from 2 regional hospitals in
Hong Kong, however, showed that (CLL) was diagnosed in
19% of Chinese patients with leukemia [1]. Alemtuzumab
has just been approved as a single agent for ﬁrst-line
therapy of chronic lymphocytic leukemia [2]. Intravenous
alemtuzumab administered in combination with ﬂudarabine
has been shown to be an eﬀective chemoimmunotherapy
regimen in CLL, even among patients with relapsed or
refractory disease who were unresponsive to prior therapy
with either agent alone [3, 4]. However, both these drugs had
tobegivenintravenously.Subcutaneous(SC)administration
ofalemtuzumabcanreducetheoccurrenceofacuteinfusion-
related reactions while maintaining therapeutic eﬃcacy
comparable to that of intravenous alemtuzumab [5, 6].
Moreover, oral ﬂudarabine has been made available, and is
found to be as eﬀective as the intravenous combination even
in combination therapy [7]. Based on these ﬁndings, we
conducted a single arm pilot clinical study to study the safety
and eﬃcacy of subcutaneous alemtuzumab in combination
with oral ﬂudarabine for the treatment of CLL, in order to
provide patients with a self-administered outpatient-based
regimen for treatment of relapsed/recurrent CLL.
2. Patients andMethods
Patients with relapsed or refractory CLL with failure of
at least one prior chemotherapy regimen were eligible to
enroll in this study, which was approved by the Institutional
Review Board of the Singapore General Hospital. Response2 Advances in Hematology
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Cycle 1: subcutaneous alemtuzumab 10mg, 20mg, 30mg, 30mg on days 1, 3, 5,and 8
oral ﬂudarabine 40mg/m2/day for 5 days
28 days interval
Cycle 2: subcutaneous alemtuzumab 30mg days 1, 3, and 5
oral ﬂudarabine 40mg/m2/day for 5 days
Cycle 3: subcutaneous alemtuzumab 30mg per month
oral ﬂudarabine 40mg/m2/day for 5 days
28 days interval
Cycle 4: subcutaneous alemtuzumab 30mg per month
oral ﬂudarabine 40mg/m2/day for 5 days
Cycle 3: subcutaneous alemtuzumab 30mg days 1, 3, and 5
oral ﬂudarabine 40mg/m2/day for 5 days
28 days interval
Cycle 4: subcutaneous alemtuzumab 30mg days 1, 3, and 5
oral ﬂudarabine 40mg/m2/day for 5 days
Cycle 5: subcutaneous alemtuzumab 30mg
oral ﬂudarabine 40mg/m2/day for 5 days
28 days interval
Cycle 6: subcutaneous alemtuzumab 30mg
oral ﬂudarabine 40mg/m2/day for 5 days
Cycle 5: subcutaneous alemtuzumab 30mg days 1, 3, and 5
oral ﬂudarabine 40mg/m2/day for 5 days
28 days interval
Cycle 6: subcutaneous alemtuzumab 30mg days 1, 3, and 5
oral ﬂudarabine 40mg/m2/day for 5 days
Figure 1: OFSA Treatment schedule. CR: Complete remission, MRD: Minimal residual disease.
to therapy was assessed based on the National Cancer
Institute Working Group criteria (NCI-WG) [8]. Evaluation
of B cell clonality and minimal residual disease (MRD) was
performed on bone marrow specimens by both DNA meth-
ods (consensus immunoglobulin heavy-chain polymerase
chain reaction) [9]a sw e l la sﬂ o wc y t o m e t r y( e s t i m a t e d
sensitivity of 0.01%) [10] after every 2 cycles of treatment.
Oral ﬂudarabine and subcutaneous alemtuzumab (OFSA)
chemotherapycomprisedinductionandconsolidationcycles
as outlined in Figure 1 and were given in 28 day cycles,
whenever feasible. In the ﬁrst induction cycle, patients
were given self-administered SC alemtuzumab 10mg, 20mg,
30mg and 30mg in dose escalation on days 1, 3, 5 and 8,
respectively,togetherwithoralﬂudarabine40mg/m2/dayfor
5 days of each 28-day cycle. For cycle 2 of induction, SC
alemtuzumab 30mg was given three times on days 1, 3, and
5 together with oral ﬂudarabine 40mg/m2/day for 5 days of
each cycle. Patients were premedicated with steroids (100mg
hydrocortisone) just before the ﬁrst dose of alemtuzumab of
the ﬁrst cycle. Depending upon response, patients received
2 to 6 cycles of induction: if complete remission (CR)
was attained without MRD negativity on four-color ﬂow
cytometry and IgH clonality assays, consolidation therapy
was given comprising SC alemtuzumab 30mg on day 1
and oral ﬂudarabine 40mg/m2/day for 5 days of each
cycle. Therapy was discontinued if molecular CR with MRD
negativity was attained. No more than 6 cycles of therapy,
whether for induction or consolidation, were administered
(Figure 1). Patients were given oral cotrimoxazole and
acyclovir prophylaxis. Cytomegalovirus (CMV) antigen (Ag)
titers were assayed for patients with fever and all blood
products were irradiated and ﬁltered. Oral paracetamol 1g
andchlorpheniramineweregivenbeforealemtuzumabinjec-
tions.IVhydrocortisone100mgwasadministeredbeforetest
dose administration during the ﬁrst induction cycle; with
monitoring of blood pressure, heart rate and temperature
were performed every 15 minutes for 1 hour after.
3. Results
3.1. Patient Characteristics. As shown on Table 1, patients
were all males with median age of 72 years (range, 60–81
years), some with other comorbidities. All 5 patients had
received at least 2 prior lines of therapy, 4 of whom had
received ﬂudarabine alone or in combination with other
chemotherapy. Recruitment was limited to ﬁve patients by
the funding available for this pilot study. The CLL-FISH
panel revealed 11q23 (consistent with ATM gene deletion)
and trisomy 12 abnormalities in 2 patients; in both cases,Advances in Hematology 3
Table 1: Patient characteristics, treatment duration, and response.
Parameters Patient no. 1 Patient no. 2 Patient no. 3 Patient no. 4 Patient no. 5
Sex Male Male Male Male Male
Age, years 72 70 81 60 74
Comorbidities Ureteric stone Benign prostatic
hypertrophy
Thyroiditis, hepatitis
B carrier
Diabetes mellitus,
hypt stomach ulcer,
hernia operation
Previous
chemotherapy CVP, FC CP, FC CVP, F CP C, F
FISH
abnormalities
(Del)11q22.3
(deletion of ATM),
trisomy 12
None
(Del)11q22.3
(deletion of ATM),
trisomy 12
(Del)13q14 (deletion
of RB1 and D13S25)
(Del)17p13.1
(deletion of p53)
Conventional
(metaphase)
cytogenetics
analysis
Numerous structural
rearrangements in 7
of 20 cells; trisomy 12
in 5 other cells
t(13;17); loss of Y
chromosome in 5
other cells
Trisomy 12; structural
rearrangement on
chromosome 13 in 1
of 20 cells
Loss of Y
chromosome in 3 cells
Complex structural
rearrangements in 2
of 18 cells
No. of induction
cycles 4222 ∗ 6
No. of
consolidation
cycles
20000
Response CR CR CR PR
∗ PR
MRD-negativity No Yes Yes No No
C = cyclophosphamide; CP = chlorambucil and prednisolone; CR = complete response; CVP = cyclophosphamide, vincristine and prednisolone; F =
ﬂudarabine; FC = ﬂudarabine and cyclophosphamide; FISH = ﬂuorescence in situ hybridization; MRD = minimal residual disease; PR = partial response.
∗Patient was lost to follow-up and did not complete protocol-speciﬁed therapy.
trisomy12wasalsorevealedusingconventionalcytogenetics,
with additional rearrangement of chromosome 13 in one
patient and multiple structural abnormalities in the other
(Table 1). The FISH panel also revealed 17p13.1 deletion
(consistent with p53 deletion) in one patient, 13q14 deletion
in one patient, whereas one patient had no chromosomal
aberrations. In the latter patient with no detectable chro-
mosomal abnormalities by FISH, conventional cytogenetics
revealed translocations between chromosomes 13 and 17.
FISH analysis was used for prognostication and not for
measurement of residual disease or clonal evolution and was
not repeated after completion of therapy.
3.2.ResponsetoTherapy. All5patientsrespondedtotherapy;
2 patients achieved a partial response (PR), 2 had an MRD-
negative CR and one had an MRD-positive CR (Table 1).
Patient no. 1 received 4 cycles of induction followed by 2
cycles of consolidation therapy and subsequently achieved a
MRD-positive CR. Patients no. 2 and no. 3 achieved a MRD-
negative CR after completing only 2 cycles of induction
therapy, and treatment was therefore halted. Patient no. 4
was lost to follow-up after 2 cycles of induction therapy
and did not complete therapy. However, he returned to
the clinic 6 months later and had relapsed, whereupon he
was given melphalan therapy, to which he did not respond.
OFSAcombinationtherapywasthenreinitiatedoﬀ-protocol,
leading the patient to achieve an MRD-positive CR. Patient
no.5achievedclearanceofbloodandmarrowlymphocytosis
albeit the persistence of a palpably enlarged spleen after
6 cycles of induction chemotherapy. He remained MRD
positive. He did not receive consolidation as the trial
allowed only for 6 cycles of therapy. The median duration
of follow-up for the 5 patients was 11 months (range,
8–13 months).
3.3. Leukocyte Response and Side Eﬀects. The mean lympho-
cyte counts of all patients fell from a mean baseline value of
63,610/µL to 42,610/µL after the ﬁrst cycle of treatment and
furtherdecreasedto1,500/µLaftercompletionof2to6cycles
of therapy. Two patients developed neutropenia, as deﬁned
by an absolute neutrophil count of less than 1,000/µL( o n eo f
whom had a neutrophil count <500/µL), but both recovered
promptly after granulocyte-colony stimulating factor (G-
CSF) administration. The platelet counts (mean 114,000/µL
prior to and 111,400/µL after therapy) and hemoglobin
levels (mean 11.7g/dL before and 11.6g/dL after therapy)
remained unaﬀected, and no patient required platelet or
red cell transfusion support during the study. CMV reac-
tivation did not occur, but 2 patients developed rapidly
reversible neutropenic sepsis requiring empiric antibiotics
and transient administration of G-CSF. More than 4 months
after completing the trial, Patient no. 1 had recurrence
of peripheral blood prolymphocytosis and disease-related
cytopenias with concurrent chryseobacterium meningosep-
ticum infection of the blood, to which he ﬁnally succumbed.
Excludingtheinitialadmission,noneofthepatientsrequired
hospitalization during the period of the trial, except for
Patient no. 1 and Patient no. 4 who were hospitalized for4 Advances in Hematology
concomitant infection and recurrence of disease 4 to 6
months after completion of therapy.
4. Discussion
There are several noteworthy observations from this study.
Four of the 5 patients responded to this combination
regimen despite failing previous ﬂudarabine treatment and
2 attained a MRD negative status. Importantly, this combi-
nation regimen was capable of inducing responses (1 CR,
1 MRD-negative CR, 1 PR) even in patients with poor-risk
cytogenetic abnormalities such as 11q and 17p deletions; this
ﬁnding is consistent with recent reports from the UK CLL02
study of SC alemtuzumab with or without oral ﬂudarabine
in patients with relapsed/refractory CLL [11]. Although no
preemptive therapy or CMV prophylaxis in the form of IV
ganciclovir or oral valganciclovir was given, symptomatic
CMV reactivation was not observed. This could be because
of small patient numbers. Overall, the SC alemtuzumab and
oral ﬂudarabine combination regimen was well tolerated
and induced promising responses in elderly patients with
relapsed CLL, including achievement of MRD negativity
in 2 patients. Importantly, this regimen provided elderly
Asian patients (four of whom were more than 70 years
of age) with a reasonably well-tolerated, self-administered,
outpatient-based treatment of relapsed/recurrent CLL. With
a median age of patients’ population of 74 years (range, 60–
81 years), this report provides evidence that the association
of ﬂudarabine and alemtuzumab is feasible also in a select
group of elderly Asian patients. These responses are also
comparable to those observed with patients from Western
countries, who are treated with alemtuzumab and ﬂudara-
bine combinations. In light of these encouraging results,
the OFSA regimen should be extended to larger multicenter
clinical trials.
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